Addiction Treatment

Two separate deals hit the wires on Tuesday. One is PharmAla Biotech's (OTC:MDXXF) with Numinus Wellness (OTC:NUMIF) for a group therapy model with MDMA, the other is Optimi Health's (OTCQX:OPTHF) with Tel Aviv University for MDMA’s potential effects on addiction treatment. PharmAla Signs...

Welcome to a new episode of our Benzinga Psychedelics Podcast. We are joined herein by executives of Clearmind Medicine (NASDAQ:CMND), a biotech company developing a proprietary, psychoactive yet non-hallucinogenic treatment for a diverse array of addictive behaviors, with Alcohol Use Disorder (aka...

Australian Coalition Calls For Psychedelic Rules Review Following roughly five months since the country’s Therapeutic Goods Administration (TGA) officially enabled the prescription of MDMA and psilocybin-assisted therapies for certain mental health conditions, a new coalition of healthcare...

Addiction treatment company Indivior PLC (NASDAQ: INDV) obtained exclusive global rights to develop, produce and commercialize Alar Pharmaceuticals’ portfolio of long-acting injectable formulations that release a prodrug1 of buprenorphine at varying durations, including its lead...